scispace - formally typeset
Open AccessJournal ArticleDOI

COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization.

Eleni Korompoki, +2 more
- 01 Aug 2021 - 
- Vol. 7, Iss: 8, pp 1113-1114
About: 
This article is published in JAMA Oncology.The article was published on 2021-08-01 and is currently open access. It has received 18 citations till now. The article focuses on the topics: Cancer.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.

Evangelos Terpos, +15 more
- 02 Aug 2021 - 
TL;DR: In this article, neutralizing antibodies against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22 and 50.
Journal ArticleDOI

Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy.

Mona Ariamanesh, +9 more
- 26 Oct 2021 - 
TL;DR: In this paper, the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients were evaluated and the results confirmed the short-term efficacy of inactivated vaccine in patients with malignancies.
Journal ArticleDOI

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

Pedro J. Pérez
TL;DR: In this paper , the authors conducted a population-based test-negative case-control study of the UK Coronavirus Cancer Evaluation Project (UKCCEP), and extracted data from the UKCCEP registry on all SARS-CoV-2 PCR test results (from the Second Generation Surveillance System), vaccination records from the National Immunisation Management Service, patient demographics, and cancer records from England, UK, from Dec 8, 2020, to Oct 15, 2021.
Journal ArticleDOI

Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.

Magdalena Benda, +14 more
- 03 Aug 2021 - 
TL;DR: In this paper, a total of 259 haemato-oncological patients were vaccinated with two 30 µg doses of BNT162b2 administered 21 days apart, and serological response was assessed by ELECSYS® Anti-SARS-CoV-2-S immunoassay before vaccination, and at 3 and 7 weeks after the first dose (T1, T2).
Journal ArticleDOI

Emerging issues related to COVID-19 vaccination in patients with cancer.

Kamal S Saini, +11 more
TL;DR: In this article, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombinia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer.
References
More filters
Journal ArticleDOI

Reinfection with SARS-CoV-2: Implications for Vaccines.

Jeffrey I. Cohen, +1 more
- 18 Dec 2020 - 
TL;DR: These findings have implications for the need of continued protective measures and for vaccines for persons previously infected with SARS-CoV-2, and as well as the duration of immunity to other viruses and virus vaccines.
Journal ArticleDOI

Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy.

John P. Moore
- 06 Apr 2021 - 
Journal ArticleDOI

Commentary: SARS-CoV-2 vaccines and cancer patients.

Chiara Corti, +1 more
- 12 Jan 2021 - 
Journal ArticleDOI

Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors.

Chang Kyung Kang, +12 more
- 09 Nov 2020 - 
TL;DR: CMI responses following influenza vaccination were stronger in ICI group than in cytotoxic chemotherapy group, and should be strongly recommended in patients with cancer receiving ICIs.
Journal ArticleDOI

COVID-19 vaccine race: watch your step for cancer patients.

Raphaelle Fanciullino, +2 more
- 02 Mar 2021 - 
TL;DR: A careful evaluation of the efficacy of these promising mRNA COVID-19 vaccines administered as lipid carriers for patients with solid tumours is needed, including a possible re-appraisal of the dosing for optimal protection of this specific and frail population.
Related Papers (3)

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.

Barliz Waissengrin, +4 more
- 01 Apr 2021 - 

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.

Leticia Monin, +51 more
- 27 Apr 2021 - 

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.

Amir Massarweh, +22 more
- 01 Aug 2021 -